

November 20, 1986

John Kane, M.D.
Director of Research
Hillside Hospital
P.O. Box 38
Glen Oaks, New York 11004

Dear John,

Enclosed are the two reports of our studies of clozapine, both published in 1979. I was not satisfied that we had done an adequate analysis of clozapine's EEG profile. I considered it an important study; first, because the compound was being reported as successful as an antipsychotic, and secondly, because if its antipsychotic activity is proven, and its EEG profile is outside that of established antipsychotic substances, it would deserve a place as a unique prototypic substance in EEG classification schemata, the head of a new class. Gil Honigfeld was unable to accommodate my further studies, but they should still be done.

I also enclose a copy of Morihisa's review of the EEG data in schizophrenic patients. The review ignores most of the earlier EEG material, but it reflects the more recent studies well.

My regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry